semaglutide anemia GLP-1 Iron Metabolism and Risk A new randomized, placebo-controlled trial

Rising global prevalence of type 2 diabetes and obesity continues to drive demand for GLP-1 receptor agonists with dual glycemic and weight management benefits

Home monitoring represents one of the most valuable tools for cardiovascular health tracking

[105] The timing of dose increases should be individualized based on patient tolerance and clinical improvement, with careful attention to the emergence of side effects that may limit further dose advancement

When Will Retatrutide Be Submitted for FDA Approval

Both MT-I and MT-II activate the MC1R receptor on melanocytes the skin cells that produce melanin pigment

June 27, 2025 the World Health Organization issued a medical product alert to health authorities worldwide regarding semaglutide and NAION